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Abstract 
Senescence accelerated mice P8 (SAMP8) is a phenotypic model of age, 
characterized by deficits in memory and altered behaviour. Here determined the 
effect of age in SAMP8, compared with the resistant strain, SAMR1, in 
behaviour and learning parameters linking these disturbances with oxidative 
stress environment. We found impairment in emotional behaviour with regard to 
fear and anxiety in young SAMP8 vs. age-mated SAMR1. Differences were 
attenuated with age. In contrast, learning capabilities are worse in SAMP8, both 
in young and aged animals, with regard to SAMR1. These waves in behaviour 
and cognition were correlated with an excess of Oxidative stress (OS) in 
SAMP8 at younger ages that diminished with age. In this manner, we found 
changes in the hippocampal expression of ALDH2, IL-6, HMOX1, COX2, 
CXCL10, iNOS, and MCP-1 with an altered amyloidogenic pathway by 
increasing the Amyloid beta precursor protein (APP) and BACE1, and reduced 
ADAM10 expression; in addition, astrogliosis and neuronal markers decreased. 
Moreover, Superoxide dismutase 1 (SOD1) and Nuclear factor-kappa beta (NF-
kβ) expression and protein levels were higher in younger SAMP8 than in 
SAMR1. In conclusion, the accelerated senescence process present in SAMP8 
can be linked with an initial deregulation in redox homeostasis, named 
neuroinflammaging, by inducing molecular changes that lead to 
neuroinflammation and the neurodegenerative process. These changes are 
reflected in the emotional and cognitive behaviour of SAMP8 that differs from 
that of SAMR1 and that highlighted the importance of earlier oxidative 
processes in the onset of neurodegeneration.  
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Introduction     
With the increase in life expectancy and aging, age-related cognitive 
impairments are becoming one of the most important issues for human health. 
Aging is a multifaceted process characterized by an intricate and irreversible 
accumulation of physiological changes, and is associated with an increase in 
transcriptional noise, aberrant production, and the maturation of many 
messenger RNA (mRNA) (López-Otín et al., 2013). Understanding the 
magnitude and physiological significance of earlier oxidative processes on 
cognitive and behavioural changes and their relationship with aging processes 
or pathological settings comprises a frontier to be crossed in order to 
prevent/treat neurodegenerative disorders (Valko et al., 2007; Bilici et al., 2001).  
The brain is especially sensitive to oxidative damage and possesses a relatively 
modest antioxidant defence (Ng et al., 2008; Halliwell et al., 2006). Oxidative 
stress (OS) has been reported as important in the pathophysiology of a number 
of age-related diseases, including Alzheimer disease (AD). AD is characterized 
by the presence of three pathological hallmarks: synapse loss; extracellular 
Senile plaques (SP), and intracellular Neurofibrillary tangles (NFT). Signs of AD 
include accelerated memory loss and alterations of mood, reason, judgment, 
and language. Both extracellular amyloid plaques and NFT are found in the 
post-mortem brains of patients with AD in the cortex, hippocampus, and 
amygdala, structures implicated in learning, memory, and emotional processes. 
The major component of SP is Amyloid beta-peptide (Aβ), shown to induce OS.  
The majority of research on AD has focused on the disease’s molecular and 
neuropathological features and on the characteristic cognitive deficits 
associated with the disorder. Although cognitive deficits are related with the 
disorder, non-cognitive symptoms are becoming increasingly important due to 
their prevalence and the dysfunctions that they generate. These non-cognitive 
symptoms, commonly referred to as “Behavioural and psychological symptoms 
of dementia” (BPSD), include abnormal motor behaviour, depression, fear, 
anxiety, and personality disorders (such as aggression and irritability). In this 
context, behavioural abnormalities such as neophobia, seizures, and increased 
aggression or locomotor activity have often been described in AD mouse 
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 4 
models (García-Mesa et al., 2011) or in the Senescence-accelerated mouse 
prone 8 (SAMP8) model (Griñan-Ferré et al., 2015), together with alterations in 
basal circadian activity. 
The role of OS in psychiatric and neurological disorders, including anxiety, has 
been the focus of many investigations (Andreotti et al., 2013; Millan et al., 2012; 
Bouayed et al., 2009; Bouayed & Bohn, 2010; Bouayed et al., 2010; Gibson et 
al., 2012). Anxiety is a normal emotional response, but when it is inappropriate, 
it constitutes a disorder (Gross et al., 2004; Weinberger, 2001). Studies in both 
humans and animals have demonstrated a strong correlation between anxiety 
and OS. It is noteworthy that several studies demonstrated that inflammatory 
cytokines increased after OS (Anderson et al., 2013; Casadesús et al., 2002; 
Ye et al., 1999; Terao A, et al., 2002). Mice expressing high cytokine levels 
present enhancement of anxiety behaviour (O’Donovan et al., 2010), and the 
overexpression of Interleukin 6 (IL-6) or Tumor necrosis factor alpha (TNF-α) 
leads to an anxiogenic phenotype (Patki et al., 2013). Therefore, in general, 
results regarding the role of inflammation in anxiety disorders suggest a relation 
between these two conditions. 
The main objective of this work was to delve deeper into the evolution of 
neuroinflammaging and its correlation with cognitive and behavioural 
parameters, including the molecular and cellular changes associated with age 
and neurodegenerative processes in SAMP8, a well-characterized model for 
studying brain aging and neurodegeneration. 
 
Experimental Procedures 
Female SAMR1 (n = 28) and SAMP8 (n = 28), 2 and 9 months of age, 
respectively, were used. These animals had free access to food and water and 
were maintained under standard temperature conditions (22 ± 2°C) and 
12h:12h light-dark cycles (300 lux/0 lux).  
Studies were performed in accordance with the Institutional Guidelines for the 
Care and Use of Laboratory Animals established by the Ethical Committee for 
Animal Experimentation at the University of Barcelona. 
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Behavioural and cognitive experiments 
 
Elevated Plus Maze  
The Elevated Plus Maze (EPM) apparatus was constructed of dark and white 
plywood (30 × 5 × 15 cm). Behaviour was scored with SMART ver. 3.0 
software, and each trial was recorded for later analysis, utilizing a camera fixed 
to the ceiling at height of 2.1 m and situated above the apparatus. The two 
closed arms were darkened with cardboard to block out the light. The arms 
radiated from a central platform (5 × 5 cm). To initiate the test session, the mice 
were placed on the central platform, facing an open arm, and allowed to explore 
the apparatus for 5 min. After the 5-min test, the mice were returned to their 
home cages, and the EPM apparatus was cleaned with 70% ethyl alcohol and 
allowed to dry between tests. Parameters recorded included time spent on open 
arms, time spent on closed arms, time spent at the centre, rearing, freezing, 
defecation, and urination. 
 
Open Field 
The Open Field (OF) apparatus was constructed of white plywood (50 × 50 × 25 
cm). Red lines were drawn to divide the floor into 25-cm squares. Behaviour 
was scored with SMART ver. 3.0 software, and each trial was recorded for later 
analysis, utilizing a camera fixed to the ceiling at a height of 2.1 m and situated 
above the apparatus. Mice were placed at the centre, or at one of the four 
corners, of the open field and allowed to explore the apparatus for 5 min. After 
the 5-min test, the mice were returned to their home cages, and the open field 
was cleaned with 70% ethyl alcohol and allowed to dry between tests. 
Behaviours scored included Locomotor Activity, Centre Stay Duration, 
Periphery Stay Duration, Freezing, Rearing, Defecation, and Urination. Each 
animal was then given a score for total locomotor activity, which was calculated 
as the sum of line crosses and number of rearing’s.  
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Novel Object Recognition Test (NORT) 
Mice were placed in a 90°, two-arm, 25-cm-long, 20-cm-high, 5-cm-wide black 
maze. The walls could be lifted off for easy cleaning. Light intensity in the 
middle of the field was 30 lux. The objects to be discriminated were made of 
plastic and were chosen not to frighten the mice, and objects with parts that 
could be bitten were avoided. Before performing the test, the mice were 
individually habituated to the apparatus for 10 min during 3 days. On day 4, the 
animals were submitted to a 10-min acquisition trial (first trial), during which 
they were placed in the maze in the presence of two identical, novel objects 
(A+A or B+B) at the end of each arm. A 10-min retention trial (second trial) was 
carried out 2 h later. During this second trial, objects A and B were placed in the 
maze and the behaviour of the mice was recorded with a camera. Time that the 
mice explored the New object (TN) and Time that the mice explored the Old 
object (TO) were measured. A Discrimination Index (DI) was defined as 
(TN−TO)/(TN+TO). In order to avoid object preference biases, objects A and B 
were counterbalanced so that one half of the animals in each experimental 
group were exposed first to object A and then to object B, whereas the 
remaining half saw object B first and then object A. The maze and the objects 
were cleaned with 96° ethanol after each test in order to eliminate olfactory 
cues.  
 
Morris Water Maze test 
An open circular pool (100 cm in diameter, 50 cm in height) was filled halfway 
with water, and water temperature was maintained at a temperature of 22°C 
± 1. Two principal perpendicular axes were defined; thus, the water surface was 
divided into four quadrants (NE, SE, SW, and NW), and five starting points were 
set (NE, E, SE, S, and SW). Four visual clues were placed on the walls of the 
tank (N, E, S, and W). Non-toxic white latex paint was added to make the water 
opaque, and a white escape platform was submerged 1 cm below the water 
level (approximately in the middle of one of the quadrants).  
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 7 
The animals’ swimming paths were recorded by a video camera mounted above 
the centre of the pool, and the data were analysed with SMART ver. 3.0 
software. The learning phase consisted of 6 days of trials for each mouse. The 
animals were submitted to five trials each day starting from the positions set (in 
random order) and without a resting phase between each trial and the 
subsequent one. At each trial, the mouse was placed gently into the water, 
facing the wall of the pool, and allowed to swim for 60 sec. If not able to locate 
the platform in this time, the mouse was guided to the platform by the 
investigator. Animals were left on the platform each time for 30 sec in order to 
allow spatial orientation. 
The parameters measured where latency time in finding the platform, time spent 
in each quadrant, and distance swum for each trial; the mean was calculated for 
each trial day. A memory test was performed at the end of the learning days, in 
which the platform was removed and the time spent by each mouse in each 
quadrant was measured. 
 
Immunodetection experiments and quantification 
After the behavioural test, the animals were intracardially perfused with a 4% 
paraformaldehyde in 0.9% NaCl solution after being anesthetized with 80 mg/kg 
of sodium pentobarbital. Brains were dissected and separated sagittally into two 
hemispheres, frozen in liquid N2, maintained at ‒80°C, and defrosted on ice 
immediately prior to homogenization procedures. For the Western blot (WB) 
experiment, aliquots of homogenized hippocampus containing 20‒30 µg of 
protein per sample were used. The protein samples were separated by Sodium 
dodecyl sulphate-Polyacrylamide gel electrophoresis (SDS-PAGE) (5–18%) and 
transferred onto Polyvinylidene difluoride (PVDF) membranes (Millipore). The 
membranes were blocked in 5% non-fat milk in Tris-buffered saline (TBS) 
solution containing 0.1% Tween 20 (TBS-T) for 1 h at room temperature, 
followed by overnight incubation at 4°C with the primary antibodies listed in 
Table 1 (Supplementary data). The membranes were then washed and 
incubated with secondary antibodies for 1 h at room temperature. 
Immunoreactive protein was viewed with the chemiluminescence-based 
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 8 
ChemiLucent™ detection kit, following the manufacturer’s protocol (ECL kit; 
Millipore), and digital images were acquired using a ChemiDoc XRS+ System 
(BioRad). Semiquantitative analyses were conducted using ImageLab software 
(BioRad), and the results were expressed in Arbitrary units (AU). Protein 
loading was routinely monitored by phenol red staining of the membrane or by 
Glyceraldehyde-3-phosphate dehydrogenase (GADPH) immunodetection. 
For immunohistochemical studies, the frozen brains were embedded in OCT 
Cryostat Embedding Compound (Tissue-Tek, Torrance, CA, USA), cut into 20-
μm-thick sections on a cryostat (Leyca Microsystems, Germany) at −20°C, and 
placed on slides. After 3 h of drying time at room temperature, the slices were 
fixed with acetone at 4°C for 10 min, allowed to dry overnight, and finally stored 
at ‒20°C until their further staining. For the staining procedure, the brain 
sections were first rehydrated by 5-min incubation in Phosphate-buffered 
solution (PBS). Afterward, the blocking/permeabilisation step was performed 
(20 min in PBS 1% Bovine serum albumin [BSA] + 1% Triton). Following two, 5-
min washings in PBS, the slices were incubated overnight at 4°C with the 
primary antibodies (see Supplementary Table 1). Two further washings were 
carried out prior to incubation with the fluorescent secondary antibody (1 h at 
room temperature, see Table 1 for dilutions). Finally, before mounting with 
Fluoromount-G™ (EMS, Hatfield, NJ, USA), nuclear staining was performed with 
Hoechst 2 µg/mL for 5 min at room temperature. Slides were allowed to dry 
overnight after mounting and image acquisition was performed with a 
fluorescence laser microscope (Olympus BX41; Germany).  At least four 
images from 4 different individuals by group were analysed with ImageJ/Fiji 
software available online from the National Institutes of Health). 
 
RNA extraction and gene expression determination 
Total RNA isolation was carried out by means of Trizol reagent following the 
manufacturer’s instructions. RNA content in the samples was measured at 260 
nm, and the purity of the samples was determined by the A260/280 ratio in a 
NanoDrop™ ND-1000 (Thermo Scientific). Samples were also tested in an 
Agilent 2100B Bioanalyzer (Agilent Technologies) to determine the RNA 
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 9 
integrity number. Reverse transcription-Polymerase chain reaction (RT-PCR) 
was performed as follows: 2 μg of messenger RNA (mRNA) was reverse-
transcribed using the High Capacity cDNA Reverse Transcription kit (Applied 
Biosystems). Real-time quantitative PCR (qPCR) was used to quantify the 
mRNA expression of aldehyde dehydrogenase 2 (ALDH2), inflammatory genes 
Interleukin 6 (IL-6), heme oxygenase (decycling) 1 (HMOX1), cyclooxygenase 2 
(COX2), C-X-C motif chemokine 10 (CXCL10), inducible nitric oxide synthase 
(iNOS), monocyte chemotactic protein 1 (MCP-1), Matrix metallopeptidase 9 
(MMP9), amyloid beta A4 precursor (PreAPP), β-secretase 1 (BACE1) and 
Disintegrin and Metalloproteinase 10 (ADAM10). Normalization of expression 
levels was performed with actin for SYBER Green and TATA-binding protein 
(Tbp) for TaqMan. The primers were as follows: for ALDH2, forward 5'- 
GCAGGCGTACACAGAAGTGA-3' and reverse 5'-
TGAGCTTCATCCCCTACCCA-3'; for IL-6, forward 5'-
ATCCAGTTGCCTTCTTGGGACTGA-3' and reverse 
TAAGCCTCCGACTTGTGAAGTGGT; for HMOX1, (Mm00516005_m1), for 
COX2, forward 5'-TGACCCCCAAGGCTCAAATA-3' and reverse 5'- 
CCCAGGTCCTCGCTTATGATC-3', for CXCL10, forward 5'- 
GGCTAGTCCTAATTGCCCTTGG-3' and reverse 5'- 
TTGTCTCAGGACCATGGCTTG-3', for iNOS, forward 5'- 
GGCAGCCTGTGAGACCTTTG-3' and reverse 5'- 
GAAGCGTTTCGGGATCTGAA-3', for MCP-1, forward 5'- 
CCCACTCACCTGCTGCTACT-3' and reverse 5'- 
TCTGGACCCATTCCTTCTTG-3', for MMP9, forward 5'- 
CTTCTCTGGACGTCAAATGTG and reverse 5'- 
AGAAGAATTTGCCATGGCAG-3', for PreAPP, forward 5'- 
AGGACTGACCACTCGACCAG-3' and reverse 5'- 
CTTCCGAGATCTCTTCCGTCT-3', for BACE1, forward 5'- 
AAGCTGCCGTCAAGTCCATC-3' and reverse 5'-
GCGGAAGGACTGATTGGTGA-3', for ADAM10, forward 5'-
GGGAAGAAATGCAAGCTGAA-3' and reverse 5'-
CTGTACAGCAGGGTCCTTGAC-3', for actin, forward 5'-
CAACGAGCGGTTCCGAT-3' and reverse 5'-GCCACAGGTTCCATACCCA-3' 
and Tbp, (Mm00446971_m1). 
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For SYBER Green, real-time PCR was performed on the Step One Plus 
Detection System (Applied Biosystems) employing the SYBR Green PCR 
Master Mix (Applied Biosystems). Each reaction mixture contained 7.5 μL of 
complementary DNA (cDNA), whose concentration was 2 μg, 0.75 uL of each 
primer (whose concentration was 100 nM), and 7.5 μL of SYBR Green PCR 
Master Mix (2X) and for TaqMan gene expression assays (Applied Biosystems), 
each 20 μL of TaqMan reaction, 9 μL cDNA (18ng) was mixed with 1 μL 20x 
probe of TaqMan Gene Expression Assays and 10 μL of 2X TaqMan Universal 
PCR Master Mix.  
Data were analysed utilizing the comparative Cycle threshold (Ct) method 
(ΔΔCt) where the actin transcript level was used to normalize differences in 
sample loading and preparation. Each sample (n = 4‒5) was analysed in 
triplicate, and the results represented the n-fold difference of transcript levels 
among different samples. 
 
Data analysis 
Data are expressed as the mean ± Standard error of the mean (SEM) from at 
least 4‒5 samples. Data analysis was conducted using GraphPad Prism ver. 6 
statistical software. Means were compared with two-way Analysis of variance 
(ANOVA) and post hoc analysis. Comparisons between groups were performed 
by unpaired Student’s t test for independent samples. Statistical significance 
was considered when p values were <0.05. Statistical outliers were performed 
out with Grubs’ test and were removed from analysis. 
In addition, partial correlation controlling for group were calculated using SPSS+ 
21.00, between the variables of interest (see figure legend for details).  
Spearman`s partial correlation coefficients between each possible pair of 
behavioural or neuronal markers were calculated with p-value adjustment for all 
to eliminate false positives correlations. 
 
Results 
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Motivational Behaviour Analysis in Female SAMR1 and SAMP8 with age 
Elevated Plus Maze (EPM) was used to determine anxiety levels in these 
models and the age evolution for the two strains. The specific anxiety value 
obtained with this paradigm, time spent closed arms, showed no changes with 
strain or age (Supplementary figure 1A); however, SAMP8 demonstrated a 
longer time spent in EPM open arms (Fig. 1A). There are strain differences in 
centre time occupation, but not between ages (significant differences for strain, 
F (1, 28) = 11.35, p = 0.0022, and age F (1, 28) = 0.02883, p = 0,8664). In 
EPM, level of freezing was significant elevated in young SAMP8, but there is a 
diminution in old SAMP8 (significant differences for age F (1, 28) = 6.674, p 
<0.01, and strain F (1, 28) = 8.600, p <0.006) (Fig. 1B). In contrast, rear 
behaviour presented a diminution in old SAMR1 and SAMP8 with respect to 
young ones, and lower levels of rears when SAMP8 was compared with age-
matched SAMR1 (significant differences in age, F (1, 28) = 34.53, p <0,0001 
and strain F (1, 28) = 16.30, p = 0.0004) (Fig. 1C). For defecation, strain 
differences were found: [F (1, 28) = 3.047, p <0.075] (Fig. 1D). Results obtained 
in the Elevated Plus Maze test (EPM) indicate that the young SAMP8 group 
exhibited changes in fear-anxiety-like behaviour. Additional parameters and 
statistical scores obtained in the EPM are listed in Table 2 (Supplementary 
data). 
Results obtained in the OFT indicated that the young SAMP8 group exhibited a 
significant increase in locomotor activity [age, F (1, 28) = 5,170, p <0.0308, and 
strain, F (1, 28) = 6,777, p <0.0146], with a higher number of rears and higher 
freezing behaviour than age-matched R1, although this latter item did not reach 
significance (Figs. 2A‒2C). In addition, young SAMP8 spent less time in the 
central zone [strain, F (1, 28) = 30.06, p ≤ 0.0014, and age, F (1, 28) = 12.56, p 
<0.0001], although reduced defecation events (Figs. 2D and 2E) as compared 
with young SAMR1 [strain, F (1, 28) = 3.407, p = 0.0755]. Additional parameters 
obtained in the OFT are listed in Table 3 (Supplementary data). Results for 9-
months old SAMP8 exhibited a clear behaviour change with regard to young 
SAMP8 and in reference to SAMR1 animals. Old SAMP8 reduced locomotor 
activity in reference to young SAMR1 and SAMP8 (p <0.01 and p <0.001, 
respectively) (Fig. 2A) Defecations and rear events decreased with respect to 
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young SAMP8 (p >0.05 (Figs. 2B and 2E). Time in centre zone and freezing did 
not change with age. 
Results indicated a higher level of stress in young SAMP8 vs. young SAMR1, 
while at later ages the behaviour was similar in the two strains. 
 
Novel Object Recognition Test (NORT) and Morris Water Maze (MWM) 
analysis in Female SAMR1 and SAMP8 with age 
In reference to learning tests, the NORT demonstrated that SAMP8 mice 
exhibited impaired memory capabilities that reached significance at 9 months in 
comparison with age-matched SAMR1 obtaining lowest Discrimination Index 
(DI) [on two-way ANOVA, analysis demonstrated significant differences for age, 
F (1, 28) = 8.782, p = 0.0061, and for strain, F (1, 28) = 19.17, p = 0.0002] (Fig. 
2F).  
The results obtained in spatial-learning acquisition and retention in the MWM 
test illustrated that all mouse groups were able to learn over the trial days, 
although SAMP8 mice exhibited a slow learning progress measured as latency 
to escape from the platform (Fig. 1E). Final acquisition of the SAMP8 group was 
worse than that of the SAMR1 at both ages studied (p <0.01 vs. age-matched 
R1). The removal test demonstrated that SAMP8 remained less time in (%) in 
the platform quadrant than age-matched SAMR1, and also demonstrated a 
lower number of entries and distance swum in the platform zone (Figs. 1F‒H). 
The distance swum by SAMP8 inside the MWM tank exhibited a circular border 
swim profile without any orientation or preference for the platform area. In 
contrast, 2-months SAMR1  showed clear directionality to the platform quadrant 
at both ages tested (Supplementary figure 2). 
 
Neuroinflammation and OS Markers in Female SAMR1 and SAMP8 
Hippocampus 
Neuroimmunological responsive parameters were determined through Glial 
fibrillary acidic protein (GFAP) expression and IL-6 genic expression. GFAP 
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expression was significant higher (in hippocampal CA3, CA1, and Dentate 
gyrus. DG) in young SAMP8 than in young SAMR1 (Figs. 3A and 3B-D), and 
only statistically significant differences were observed in the DG in SAMR1 old 
mice (For statistics details see figure notation). In reference to inflammation 
mediator results, higher expression of IL-6, CXCL10, ALDH2, HMOX1, MCP-1, 
COX2, iNOS, and MMP9 were determined in young SAMP8 hippocampus than 
in young SAMR1 (Figs. 4A‒H). Expression of IL-6 and MCP-1 were significantly 
lower in old SAMP8 than in young mice, reaching values nearest to those of old 
SAMR1, although remaining significantly higher. HMOX1, CXCL10, and iNOS 
expression levels were maintained higher in old SAMP8 compared with old 
SAMR1, whereas COX2 levels increased in the old SAMR1 strain. ALDH2 
expression was diminished in SAMP8 at all ages studied, indicating a lower 
capability for responding to OS than SAMR1. No significant changes in MMP9 
were detected. 
Additionally, protein levels of 4-Hydroxynonenal (4-HNE) and Superoxide 
dismutase 1 (SOD1) were studied. Results showed significantly higher levels of 
these OS markers in SAMP8 with regard to SAMR1 at any ages of the studied 
(for statistics details see figure notations) (Figs. 4I and 4L). Conversely, the p65 
active fraction of Nuclear factor-kappa beta (NF-kβ) was found at the same 
levels in young mice (SAMP8 and SAMR1) and decreased in old SAMP8 
(p<0.05) (Figs. 4I and 4J). 
 
Neurodegeneration and AD parameters in Female SAMR1 and SAMP8 
Hippocampus 
NeuN, Bax protein, tau phosphorylation, and the Amyloid precursor protein 
(APP) pathway were studied as indicative of the neurodegeneration process. 
Immunohistochemical staining indicated lower NeuN hippocampal levels in 
SAMP8 at the ages studied vs. SAMR1 (Figs. 5A and 5B-D). Increased Bax 
protein expression was found in SAMP8 vs. SAMR1 both at 2 and at 9 months 
of age (Figs. 4I and 4M). In reference to tau post-transcriptional modification, 
phosphorylation in Ser199 and Ser396 were studied. Results showed an 
increase in tau hyperphosphorylation in SAMP8 compared with SAMR1 [pTau 
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Ser 199, Strain: F (1, 8) = 43.36, p = 0.0002; Age: F (1, 8) = 17.14, p = 0,0033 ; 
pTau Ser396, Age: F (1, 8) = 28.59, p = 0.0007] (Figs. 6A‒C). APP pathway 
was found also increased in SAMP8; in this respect, SAMP8 presented a 
significant diminution in ADAM10 gene expression compared with SAMR1 at all 
ages studied, but an increase in APP gene expression and higher BACE1 
expression at younger ages in SAMP8 with significant increase in sAPPβ and 
BACE1 protein levels, accompanied by reduced sAPPα (For statistic details see 
figure notations) (Figs. 10D-K).  
Finally, partial correlation analysis determined the robust relationship among the 
cognitive, behaviour, OS, inflammaging, neurodegenerative and AD parameters 
evaluated through the work in young and old SAMP8 and SAMR1 (Table 4 and 
Fig. 7).  
 
Discussion 
It has been described that with age, OS increases, and this oxidative 
environment plays a nuclear role in the senescence process. The focus of the 
work was to explore the possible effects of OS on ageing and their correlation 
with emotional disorders, such as anxiety and cognitive decline, and we 
employed herein SAMP8, a well-characterized model for studying brain aging 
and neurodegeneration. SAMP8 mice present signs of accelerated aging in 
several organic systems, such as skin, skeletal muscle, eyes, vessels, and 
brain, display a short life span (10.2 months) compared with control strain 
SAMR1 mice (Nomura et al., 1999; Morley et al., 2012a). SAMP8 has been 
studied as a non-transgenic murine model for accelerated senescence and late-
onset AD (Pallàs et al., 2008). These mice exhibited cognitive and emotional 
disturbances from young ages, probably due to brain pathological hallmarks 
such as OS, inflammation, and activated neuronal death pathways, mainly 
affecting the brain’s cortex and hippocampus (Takeda, 2010).  
Here, we established that young female SAMP8 had raised neurodegenerative 
and cognitive/emotional disturbances induced by an oxidant environment that 
fostered changes in the molecular markers of inflammation, gliosis, tau 
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hyperphosphorylation, and Bax (Fig. 7 and Table 4). The majority of these 
desynchronized parameters normalized with aged SAMR1, indicating that these 
adverse conditions at young ages occur based in accelerated senescence in 
this mouse model of aging. 
 
The behavioural tests applied demonstrated that young SAMP8 presented, on 
the whole, anxiety and restless, fearful behaviour, with higher locomotion and 
rears, avoiding the OF centre zone. This anxious behaviour reduced with age, 
resembling that of old SAMR1. As expected, cognitive impairment occurs earlier 
in female SAMP8 than in SAMR1. Behaviour and cognitive changes in SAMP8 
in comparison with SAMR1 were demonstrated in males but, to our knowledge, 
this is the first time that these have been demonstrated in female SAMP8. 
 
Inflammaging, in brain “neuroinflamm-aging”, is a current concept that involves 
changes in molecular, biochemical, and cellular changes or processes that are 
implicated in senescence. Moreover, growing evidence suggests that the brain 
tissues of patients with AD are characterized early by greater OS. This process 
is included in whole, increased OS, altered expression in OS mediators, gliosis, 
and neurodegeneration. For instance, numerous studies indicate that 
hemeoxygenase is a major cell-adaptive responder to stress (Sanli et al., 2014).  
Because altered inflammatory marker levels are described in SAMP8, here we 
screened some of the most important gene expression proteins, such as 
cytokines HMOX1, CXCL10, COX2, and iNOS, or protein levels of SOD1, of a 
NF-kβ complex member (p65), and of 4-HNE, a by-product of protein oxidation 
implicated in the oxidative process and that subsequently participates in 
neuroinflammation.   
 
The results obtained here exhibited higher gene expression of IL-6, HMOX1, 
CXCL10, COX2, and iNOS in 2-month-old SAMP8 vs. SAMR1, demonstrating 
that neuroinflammation is present at early ages in SAMP8, rendering the 
oxidative environment that would occur at the starting point of the senescence 
process in these mice. Moreover, consistent with OS parameters and 
behavioural results, the SAMP8 group exhibited a significant difference related 
with hippocampal integrity compared with SAMR1, measured by the loss in 
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NeuN immunostaining in the hippocampus. NeuN is localized at the core of the 
majority of neural cells during development, is expressed in post-mitotic 
neurons from early stages of differentiation, and its expression persists in the 
adult (Mullen et al., 1992). These results are in agreement with a number of 
reports in which insufficient neurogenesis is demonstrated in SAMP8 to 
compensate for neuronal loss during aging and neurodegeneration (Gang et al., 
2011; Díaz-Moreno et al., 2013; Griñan-Ferré et al., 2015). 
 
Additionally, our results demonstrated an increase in Bax protein and in the 
level of hyperphosphorylated tau forms, clearly indicative that the 
neurodegenerative process has been initiated at these young ages in SAMP8. 
Neuronal altered markers were reflected in impairment in the learning 
capabilities shown  in MWM and NORT, and also in the emotional disturbances 
described in young SAMP8 (Griñan-Ferré et al., 2015), thus reinforcing the key 
role of the initial oxidative process in the SAMP8 senescence phenotype.  
 
Increases in tau phosphorylation were reported in 5-month-old SAMP8 males 
(Canudas et al., 2005) and a time-dependent accumulation of 
hyperphosphorylated tau in SAMP8 males (Casadesús et al., 2012). It is 
noteworthy that here we demonstrated the increase in p-Tau (Ser199) and p-
Tau (ser396) in the hippocampus as early as 2 months in SAMP8. Tau 
phosphorylation increases have been linked with OS (Castellani et al., 2008; 
Moreira et al., 2010) and also with SAMP8 (Casadesús et al., 2012). Some 
authors claim a compensatory role of phospho tau driven by cells against OS 
that serves a protective function (Bonda et al., 2011). In control-strain SAMR1, 
tau did not increase its phosphorylated state and indeed did increase in aged 
mice, indicating that OS is lower in the SAMR1 brain; thus, this possible 
compensatory effect is not required. Lower OS in SAMR1 was demonstrated 
because levels of oxidative markers such as MCP-1, IL-6, iNOS, CXCL10, and 
HMOX1 did not change with age in SAMR1, and NF-kβ is indeed lower in aged 
SAMR1. 
Alteration in APP processing is also postulated with an earlier onset of AD. OS-
induced BACE activity and sAPPβ levels were suppressed by gamma (γ)-
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secretase inhibitors (Jo et al., 2010). Activities of both enzymes were greater in 
brain-tissue samples from patients with AD, and protein levels of BACE1 were 
elevated in 3xTg-AD mice, thus the OS-induced expression of BACE1 resulting 
in excessive Aβ production in AD (Jo et al., 2010). In 2-month-old SAMP8, in 
addition to an increase in APP gene expression, a misbalance in the APP 
amyloidogenic pathway was demonstrated with increases in BACE1 and 
reduced ADAM10 gene and protein expression; both are secretases implicated 
in APP processing and the generation of amyloid beta. It is noteworthy that OS 
is also implicated in the enzymatic activity of secretases (Mounton-Liger et al., 
2012), and the pattern exhibited by young female SAMP8 demonstrated that 
increased OS gave rise to disturbances in APP processing similar to those 
involved in the occurrence of AD when ageing SAMP8 and SAMR1 presented 
similar APP pathway processing but, as noted, this appeared earlier in SAMP8, 
correlating with behavioural disturbances and cognitive deficits. 
IL-6 is involved in the pathogenesis of neurodegenerative diseases such as AD 
(Quintanilla et al., 2004). In the nervous system, IL-6 mainly occurs in activated 
glia, such as astrocytes and microglial cells. Our results demonstrated a 
significant increase in IL-6 genic expression in the SAMP8 compared with the 
SAMR1 group, suggesting an alteration in inflammatory processes gated to the 
SAMP8 strain that impairs SAMR1 on ageing. A higher degree of 
neuroinflammation in young SAMP8 correlated with earlier cognitive impairment 
and the initial neurodegenerative process in these mice. The more normalized 
or equal inflammation levels in aged SAMP8 when compared with SAMR1, 
denoting accelerated senescence in the SAMP8 strain, is correlated with 
inflammaging and the neuroinflammation process at earlier ages.  
In this respect, the SAMP8 model fits as a useful tool to study earlier 
inflammaging changes and neurodegenerative processes at late ages. 
Therefore, young SAMP8 can be used to study the initial and key step of the 
senescence process that leads, in elderly SAMP8, to cognitive impairment and 
neurodegeneration.  
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Figure legends 
 
Figure 1. Results of Elevated plus maze (EPM) and  Morris water maze (MWM) 
in SAMR1 and SAMP8 at 2 and 9 months. For EPM test: Time spent in open 
arms (A), freezing (B), rears (C) and defecations (D). Results of spatial learning 
and memory: Escape latency time to reach the hidden platform during training 
days (E), percentage time spent in platform zone during 60 s probe trial of 
MWM test (F), number of entries in platform zone during 60 s probe trial of 
MWM test (G), trail distance in platform zone during 60 s probe trial of MWM 
test (H). Data represented as observed mean ± Standard error of the mean 
(SEM); (n = 14 for each group). *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001*. 
 
Figure 2. Results of Open field test in SAMR1 and SAMP8 at 2 and 9 months. 
Locomotor activity (A), rears (B), freezing (C), time spent in centre zone (D), 
defecations (E). Results of Discrimination index of Novel Object recognition 
testes (NORT) (F). Data represented as observed mean ± Standard error of the 
mean (SEM) (n = 14 for each group). *p<0.05; **p<0.01; ***p<0.001; 
****p<0.000. 
 
Figure 3. Representative images for GFAP immunostaining (A) and 
quantification on the bar chart (B-D) in SAMR1 and SAMP8 at 2 and 9 months. 
Bars represent mean ± Standard error of the mean (SEM); (n = 4 for each 
group). ***p<0.001; ****p<0.0001. CA: Cornu Amonis, DG: Dentate Gyrus. 
Scale bar for immunohistochemical images is 200 μm.  
 
Figure 4. Pro-inflammatory and oxidative stress gene expression in SAMR1 
and SAMP8 at 2 and 9 months for IL-6 (A), MCP-1 (B), HMOX1 (C), CXCL10 
(D), iNOS (E), COX2 (F), ALDH2 (G), MMP9 (H). Gene expression levels were 
determined by real-time PCR. Representative Western blot for NF-κB, SOD1, 4-
HNE and Bax (I), and quantifications (J-M). Mean ± Standard error of the mean 
(SEM) from five independent experiments performed in triplicate are 
represented. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. 
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Figure 5. Representative images for NeuN immunostaining (A) and 
quantification on the bar chart (B-D) in SAMR1 and SAMP8 at 2 and 9 months. 
Bars represent mean ± Standard error of the mean (SEM); (n = 4 for each 
group; CA: Cornu Amonis; DG: Dentate Gyrus. Scale bar for 
immunohistochemical images is 200 μm; ***p<0.001; ****p<0.0001. 
 
Figure 6. Representative Western blot for p-Tau (Ser199), p-Tau (Ser396) and 
Tau total (A), sAPPα, sAPPβ and BACE1 (D), and quantifications (B-C, E-G). 
Beta-amyloid pathway gene expression in SAMR1 and SAMP8 at 2 and 9 
months for Amyloid Beta (A4) precursor (H), ADAM10 (I) and BACE1 (K). Gene 
expression levels were determined by real-time PCR. Mean ± Standard error of 
the mean (SEM) from five independent experiments performed in triplicate are 
represented. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. 
 
Figure 7. Behavioral and neuronal markers hierarchical network of the SAMR1 
and SAMP8 at two ages (n=56) obtained by using yEd graph editor (v. 3.14.4). 
Each node represents one behavioral or neuronal marker and each edge 
between two nodes represents the partial correlation. Colors represent the 
different variables and node dimensions represent Behavioral and neuronal 
markers hierarchical network of the SAMR1 and SAMP8 at two ages the 
number of correlations. Solid black line represents positive correlation and 
dotted red line represents negative correlation.  
 
Table 4: Partial correlation controlling for group coefficients between selected variables included in the study. 
 
 
 
 
 
The values used to calculate Partial correlation controlling for group coefficients were behavioral parameters (showed in Figures 1E, 2C, 3 and 4B); protein 
levels (showed in Figures 7B-E, 9B-C and 10B-D); gene expression (showed in Figures 6A-H and10E-G) and Immunochemistry (showed in Figures 5B and 8B). 
Correlation (2-tailed) is significant * p<0.05; **p<0.01 and ***p<0.001; (-) Negative covariation of two variables. 
 DI Platform
time (%) 
MWM 
Rears (n) 
OF 
Freezing 
(sec) 
EPM 
IL-6 CXCL10 COX2 iNOS ALDH2 HMOX1 MCP-1 ADAM10 Amyloid 
precurso
r (A4) 
SOD1 Bax 4-HNE BACE1 Ratio 
pTau199 
Ratio 
pTau396 
NF-Kβ sAPPα sAPPβ GFAP NeuN 
DI 1 0,435* 0,164 0,027 -0,277 -0,249 0,05 -0,626* -0,068 -0,479 -0,153 0,298 -0,223 -0,563** -0,439* -0,312 -0,182 -0,313 -0,455* -0,076 0,12 -0,677*** 0,064 0,714*** 
Platform 
time (%) 
MWM 
 1 0,135 -0,003 -0,264 0,03 0,283 -0,564
*
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*
 -0,244 0,581
*
 -0,353 -0,747
***
 -0,512
*
 -0,494
*
 -0,196 -0,408 -0,477
*
 -0,027 0,265 -0,76
***
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***
 
Rears (n) 
OF 
  1 0,677** 0,682** -0,423 0,127 0,243 0,159 0,297 0,749** -0,353 0,067 -0,332 -0,009 -0,669*** -0,79*** -0,733*** -0,636** 0,693*** -0,067 -0,522 0,716*** 0,534** 
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(sec) 
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**
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***
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**
 -0,448 -0,048 0,493 
iNOS        1 0,449 0,803 0,392 -0,389 0,275 0,346 0,62
*
 -0,422 -0,485 -0,341 0,451 0,686
**
 -0,549
*
 0,128 0,32 -0,228 
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 0,324 -0,302 0,554
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 0,315 0,468 -0,06 -0,262 0,078 0,119 0,6
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r (A4) 
            1 0,149 0,646** -0,105 -0,332 -0,099 0,007 0,561* -0,284 0,058 0,353 0,07 
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**
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Bax               1 -0,111 -0,43
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 -0,271 0,149 0,579
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***
 0,302 0,063 -0,487
**
 0,654
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 -0,055 -0,575
**
 0,108 
BACE1                 1 0,66
**
 0,377 -0,795
***
 0,559
**
 0,137 -0,88
***
 -0,196 
Ratio 
pTau199 
                 1 0,611
**
 -0,456
*
 -0,085 0,441
*
 -0,782
***
 -0,616 
Ratio 
pTau396 
                  1 -0,168 -0,39 0,601** -0,559** -0,679*** 
NF-KB                    1 -0,566
**
 0,013 0,705
***
 0,047 
sAPPα                     1 -0,468* -0,298 0,518* 
sAPPβ                      1 -0,298 -0,646
**
 
GFAP                       1 0,552
**
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Griñán-Ferré	et	al.,	Figura	3.		
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Griñán-Ferré	et	al.,	Figura	5.	
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Griñán-Ferré	et	al.,	Figure	7.		
	
The	network	was	calculated	using	yEd	graph	editor	version	3.14.4.	
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Table 1. Antibodies used in Western blot and Inmunohistochemical studies. 
Antibody Host Source/Catalog 
 WB 
dilution 
ICH 
dilution 
Bax Rabbit Cell Signaling/#2772 1:1000  
BACE1 Rabbit Cell Signaling/D10E5 1:1000  
4-HNE Rabbit Abcam/ab46545 1:1000  
SOD1 Sheep Calbiochem/574597 1:1000  
sAPPα Rabbit Covance/SIG-39139-005 1:1000  
sAPPβ Rabbit Covance/SIG-39138-050 1:1000  
p65 Rabbit Cell Signaling/D14E12 1:1000  
GAPDH Mouse Millipore/MAB374 1:2000  
NeuN Mouse Millipore/MAB377 1:1000 1:100 
GFAP Mouse Abcam/ab48050-100  1:400 
p-Tau s396 Rabbit Invitrogen/44752G 1:1000  
Tau total Goat Santa cruz/sc-1995 1:1000  
p-Tau s199 Rabbit Invitrogen /44734G 1:1000  
Alexa Fluor 546 donkey anti-
rabbit IgG A 
 
Molecular probes/ 
AF488:A21202 
 
1:400 
Alexa Fluor 488 donkey anti-
mouse IgG A Alexa 
 
Molecular 
probes/AF555:A31572 
 
1:250 
Donkey-anti-goat HRP 
conjugated 
 Santa Cruz Biotech/ sc-2020 1:3000 
 
Goat-anti-mouse HRP 
conjugated 
 Biorad/# 170-5047 1:2000 
 
Goat-anti-rabbit HRP 
conjugated 
 Cell Signaling/# 7074 1:2000 
 
 
  
Supplemental Data
 
 
Table 2. Parameters measured in the Elevated Plus Maze Test (EPM). Results 
are expressed as mean ± Standard error of the mean (SEM). *p <0.05; **p 
<0.05; ***p<0.001 vs SAMR1, 2 months. #p <0.05; ##p <0.001 vs SAMP8, 2 
months. $p<0.05 vs SAMR1, 9 months. 
 
 SAMR1 
2 months 
SAMP8 
2 months 
SAMR1 
9 months 
SAMP8 
9 months 
Time in zone-
Center (sec), 
a 
64.12 ± 4.24 67.56 ± 5.11 50.05 ± 6.42 48.29 ± 3.55
#
 
Time in zone- 
Open Arms 
(sec), b 
49.64 ± 3.06 67.97 ± 7.69* 48.64 ± 7.86 82.65 ± 9.98*,$ 
Time in zone- 
Closed Arms 
(sec), c 
186.53 ± 6.40 164.63 ± 11.36 201.25 ±9.91 169.02 ± 12.66 
Freezing 
(sec), d 
1.98 ± 0.47## 36.86 ± 11.58** 4.33 ± 1.64## 3.99 ± 1.28## 
Rearings (n), 
e 
24.71 ± 1.67 21.13 ± 1.80 18.38 ± 1.55* 9.88 ± 
0.72****,####,$$ 
Defecations 
(n), f 
0.29 ± 0.18 1.25 ± 0.31* 1.00 ± 0.33 0.88 ± 0.40# 
Urinations 
(n), g 
0.00 ± 0.00 0.00 ± 0.00 0.38 ± 0.18 0.38 ± 0.18 
 
 
 
 
 
 
 
 
Table 3. Parameters measured in the Open Field Test (OFT). Results are 
expressed as a mean ± Standard error of the mean (SEM). *p <0.05; **p <0.05; 
***p<0.001 vs SAMR1, 2 months. #p <0.05; ##p <0.001 vs SAMP8, 2 months. 
$p<0.05 vs SAMR1, 9 months. 
 
 SAMR1 
 2 months 
SAMP8 
2 months 
SAMR1 
9 months 
SAMP8 
9 months 
Total 
Distance 
(cm), a 
2,297.92 ± 
63.72* 
2,706.36 ± 
140.98* 
2,676.39 ± 
80.67 
1,850.20 ± 
56.41**,####,$$$$ 
Distance in 
Zone Center 
(cm), b 
466.26 ± 46.25 355.16 ± 
41.60 
286.86 ± 
22.51 
181.21 ± 13.27 
Entries into 
Zone 
Periphery , c 
1,831.08 ± 
60.32 
2,351.20 ± 
112.87 
2,389.53 ± 
71.85 
1,669.00 ± 
48.91 
Center (%), 
d 
20.23 ± 1.82 12.95 ± 
1.10*** 
10.70 ± 
0.73**** 
9.75 ± 0.58****  
Periphery 
(%), e 
79.77 ± 1.82 87.05 ± 1.10 89.31 ± 0.73 90.25 ± 0.58 
Freezing 
(sec), f 
4.64 ± 1.05 8.28 ± 2.72 4.28 ± 0.99 6.48 ± 1.42 
Rearings 
(n), g 
20.71 ± 2.44 37.00 ± 
2.91**** 
25.75 ± 1.64 15.00 ± 
1.58####,$$ 
Defecations 
(n), h 
2.14 ± 0.59 0.25 ± 0.16* 1.63 ± 0.40 2.00 ± 0.38$ 
Urinations 
(n), i 
0.29 ± 0.18 0.13 ± 0.13 0.50 ± 0.29 0.75 ± 0.25 
 
 
 1 
Supplementary 1. Results of Elevated plus maze in SAMR1 and SAMP8 at 2 
and 9 months. Time spent in closed arms (A), time spent in centre (B). Data 
represented as observed mean ± Standard error of the mean (SEM); (n = 14 for 
each group). *p<0.05. 
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Supplementalfigures
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Supplementary 2. Representative swimming paths in SAMR1 and SAMP8 at 2 
and 9 months during 60 s probe trial of MWM.  
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